文献速递主动脉疾病外周动脉疾病

主动脉瘤的抗血栓治疗:系统综述与Meta分析

Antithrombotic Therapy for Aortic Aneurysms: A Systematic Review and Meta-Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-07-16

该系统综述与Meta分析检索Medline、Embase和CENTRAL数据库,纳入59项研究共122 102例主动脉或外周动脉瘤患者。抗血小板治疗与腹主动脉瘤(AAA)干预后长期全因死亡率降低相关(HR 0.84),抗凝治疗与全因死亡率升高(HR 1.64)、三年内内漏(OR 1.99)及一年再干预率升高(OR 3.25)相关。作者认为仍缺乏高质量数据,需要大型设计良好的试验。

要点

  • 抗血小板治疗与AAA干预后长期全因死亡率降低相关(HR 0.84,95%CI 0.76-0.92)。
  • 抗凝治疗与AAA干预后全因死亡率升高(HR 1.64,95%CI 1.14-2.37)相关。
  • 抗凝治疗与三年内内漏(OR 1.99)及一年再干预率升高(OR 3.25)相关。

核心结论

  • 缺乏评估动脉瘤患者抗血栓治疗的高质量数据。
  • 抗血小板治疗与AAA干预后全因死亡率降低相关,而抗凝治疗与全因死亡率、内漏及再干预风险升高相关。
  • 仍需大型设计良好的试验来确定抗血栓药物在此情况下的治疗获益。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase和CENTRAL数据库。
  • 纳入随机对照试验和观察性研究,评估抗血栓治疗对任何主动脉或外周动脉瘤患者临床结局的影响。
  • 共纳入59项研究(28项抗血小板药物、12项抗凝药物、2项术中肝素、16项任何抗血栓药物),涉及122 102例患者。

主要发现

  • AAA生长速率与使用抗血小板治疗无显著关联(SMD -0.36 mm/年;95%CI -0.75至0.02;p=0.060;GRADE证据确定性:极低)。
  • 抗血栓药物与接受干预的AAA患者30天死亡率升高相关(OR 2.30;95%CI 1.51-3.51;p<0.001;GRADE证据确定性:低)。
  • 干预后,抗血小板治疗与长期全因死亡率降低相关(HR 0.84;95%CI 0.76-0.92;p<0.001;GRADE证据确定性:中等)。
  • 干预后,抗凝药物与全因死亡率升高相关(HR 1.64;95%CI 1.14-2.37;p=0.008;GRADE证据确定性:极低)。
  • 抗凝药物与三年内内漏(OR 1.99;95%CI 1.10-3.60;p=0.020;I²=60%;GRADE证据确定性:极低)及一年再干预率升高(OR 3.25;95%CI 1.82-5.82;p<0.001;I²=35%;GRADE证据确定性:中等)相关。

关键数值与推荐

  • AAA生长速率与抗血小板治疗:SMD -0.36 mm/年(95%CI -0.75至0.02;p=0.060;GRADE证据确定性:极低)。
  • 接受干预的AAA患者30天死亡率与抗血栓药物:OR 2.30(95%CI 1.51-3.51;p<0.001;GRADE证据确定性:低)。
  • 干预后长期全因死亡率与抗血小板治疗:HR 0.84(95%CI 0.76-0.92;p<0.001;GRADE证据确定性:中等)。
  • 干预后全因死亡率与抗凝药物:HR 1.64(95%CI 1.14-2.37;p=0.008;GRADE证据确定性:极低)。
  • 三年内内漏与抗凝药物:OR 1.99(95%CI 1.10-3.60;p=0.020;I²=60%;GRADE证据确定性:极低);一年再干预率与抗凝药物:OR 3.25(95%CI 1.82-5.82;p<0.001;I²=35%;GRADE证据确定性:中等)。

临床怎么用

  • 作者认为,抗血小板治疗与AAA干预后全因死亡率降低相关,而抗凝治疗与全因死亡率、内漏及再干预风险升高相关。
  • 作者认为,仍需大型设计良好的试验来确定抗血栓药物在动脉瘤患者中的治疗获益。

局限性

  • 缺乏评估动脉瘤患者抗血栓治疗的高质量数据。
  • 五项研究探讨腘动脉瘤的抗血栓治疗,因异质性无法进行Meta分析。
  • 仍需大型设计良好的试验来确定抗血栓药物在此情况下的治疗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The role of antithrombotic therapy in the management of aortic and peripheral aneurysms is unclear. This systematic review and meta-analysis aimed to assess the impact of antithrombotics on clinical outcomes for aortic and peripheral aneurysms. METHODS: Medline, Embase, and CENTRAL databases were searched. Randomised controlled trials and observational studies investigating the effect of antithrombotic therapy on clinical outcomes for patients with any aortic or peripheral artery aneurysm were included. RESULTS: Fifty-nine studies (28 with antiplatelet agents, 12 anticoagulants, two intra-operative heparin, and 16 any antithrombotic agent) involving 122 102 patients were included. Abdominal aortic aneurysm (AAA) growth rate was not significantly associated with the use of antiplatelet therapy (SMD -0.36 mm/year; 95% CI -0.75 - 0.02; p = .060; GRADE certainty: very low). Antithrombotics were associated with increased 30 day mortality for patients with AAAs undergoing intervention (OR 2.30; 95% CI 1.51 - 3.51; p < .001; GRADE certainty: low). Following intervention, antiplatelet therapy was associated with reduced long term all cause mortality (HR 0.84; 95% CI 0.76 - 0.92; p < .001; GRADE certainty: moderate), whilst anticoagulants were associated with increased all cause mortality (HR 1.64; 95% CI 1.14 - 2.37; p = .008; GRADE certainty: very low), endoleak within three years (OR 1.99; 95% CI 1.10 - 3.60; p = .020; I2 = 60%; GRADE certainty: very low), and an increased re-intervention rate at one year (OR 3.25; 95% CI 1.82 - 5.82; p < .001; I2 = 35%; GRADE certainty: moderate). Five studies examined antithrombotic therapy for popliteal aneurysms. Meta-analysis was not possible due to heterogeneity. CONCLUSIONS: There was a lack of high quality data examining antithrombotic therapy for patients with aneurysms. Antiplatelet therapy was associated with a reduction in post-intervention all cause mortality for AAA, whilst anticoagulants were associated with an increased risk of all cause mortality, endoleak, and re-intervention. Large, well designed trials are still required to determine the therapeutic benefits of antithrombotic agents in this setting.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Wong KHF, Zlatanovic P, Bosanquet DC, et al. Antithrombotic Therapy for Aortic Aneurysms: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2022. PMID: 35853579. doi:10.1016/j.ejvs.2022.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。